Effect of normobaric intermittent hypoxia-hyperoxia in patients with post-acute-COVID-19 syndrome
- Conditions
- post-acute COVID Syndrom
- Registration Number
- DRKS00031515
- Lead Sponsor
- Otto-von-Guericke-Universität Magdeburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 33
•Persistent COVID-19 related symptoms at least 4 weeks after the manifestation of the first acute symptoms
•At least 30 days since recovery from clinical signs or medical discharge (if they have been hospitalized due to acute COVID-19 syndrome)
•Tested positive to COVID-19
•The need of intensive care
•Current smoker and excessive use of alcohol or drugs
•Pregnancy
•Mental disease (e.g., MCI, dementia, schizophrenia, severe depression)
•Uncontrolled cardiovascular disease (e.g., hypertension, angina pectoris, heart failure, arrhythmia)
•Uncontrolled diabetes
•Chronic renal dysfunction
•Severe non-cardiac diseases such as cancer, anaemia that limit participation in the study
•Inability to accept the procedure of breathing through a face-mask
•Need for continuous or intermittent oxygen therapy
•Exposure to altitudes >1500m in the last 3 months
•Exacerbation of chronic diseases, requiring a change in patient management
•Taking part in less than 75% of the total sessions planned
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method One day prior (pre-test) and two days after (post-test) the start and end of the intervention, respectively: <br>Trait Fatigue as well as motor performance fatique and perceived motor performance fatigue (via Sit-to-Stand Test, 15-point Borg Scale, Borg's category ratio-10 Scale, 11-point Feeling-Scale, 6-point felt arousal Scale, Fatigue Severity Scale, Fatigue Scale for Motor and Cognitvie Function)
- Secondary Outcome Measures
Name Time Method One day prior (pre-test) and two days after (post-test) the start and end of the intervention, respectively: <br>i) Quality of life and psycho-emotional state (via 12-Item Health Survey, Depression, Anxiety and Stress Scale-21, Beck Depression Inventory II, Pittsburgh Sleep Qiality Index)<br>ii) Executive functions (via Go no Go Task, Simon-Task, Trail Making Test A+B, Sternberg Test, Digit Span Backwards Task)<br>iii) Walking distance in 6-minute walk test<br>iv) Handgrip strength (via isometric hand grip dynamometre)<br>v) Pulmonary function<br>vi) Blood parameters (IL-10, IL-6, TNF-1a, CRP-2, CRP-1 genotype).<br><br>Immediately before and 10 minutes as well as 4.5 hours after the first intervention:<br>Erythropoetin (blood serum)